Brucella melitensis, one of the causative agents of human
brucellosis, causes acute, chronic, and relapsing
infection. While T cell immunity in
brucellosis has been extensively studied in mice, no recognized human
T cell epitopes that might provide new approaches to classifying and prognosticating B. melitensis
infection have ever been delineated. Twenty-seven pools of 500 major histocompatibility complex class II (MHC-II) restricted
peptides were created by computational prediction of promiscuous MHC-II CD4(+) T cell derived from the top 50
proteins recognized by
IgG in human sera on a genome level B. melitensis
protein microarray.
Gamma interferon (IFN-γ) and
interleukin-5 (IL-5)
enzyme-linked immunospot (ELISPOT) analyses were used to quantify and compare Th1 and Th2 responses of leukapheresis-obtained peripheral blood mononuclear cells from Peruvian subjects cured after acute
infection (n = 9) and from patients who relapsed (n = 5). Four
peptide epitopes derived from 3 B. melitensis
proteins (BMEI 1330, a DegP/HtrA
protease; BMEII 0029,
type IV secretion system component VirB5; and BMEII 0691, a predicted
periplasmic binding protein of a
peptide transport system) were found repeatedly to produce significant IFN-γ ELISPOT responses in both acute-
infection and relapsing patients; none of the
peptides distinguished the patient groups.
IL-5 responses against the panel of
peptides were insignificant. These experiments are the first to systematically identify B. melitensis MHC-II-restricted CD4(+)
T cell epitopes recognized by the human immune response, with the potential for new approaches to
brucellosis diagnostics and understanding the immunopathogenesis related to this intracellular pathogen.